Development of a novel score to predict probability of growth without growth hormone after resection of paediatric craniopharyngiomas: relative to tumour growth pattern.

Plain-language guide to PMID 31853886 (2020): clinical trial of Exogenous HGH, sermorelin & older GHRPs (why they're passed over) in 708 patients.

Key Facts

PMID: 31853886
Journal: Journal of endocrinological investigation
Year: 2020
Study type: Clinical Trial
Authors: Peng JX et al. (7 authors)
DOI: 10.1007/s40618-019-01154-y
Registered trial: NCT00949156

What This Study Did, in Plain Language

What Was Tested

Researchers studied Exogenous HGH, sermorelin & older GHRPs (why they're passed over) in this clinical trial publication.

The researchers aimed to develop a novel clinical score to predict the probability of GWGH in PCs.

Who Took Part

According to the abstract, 708 patients were involved.

PubMed indexes the participants as children, both men and women.

A total of 708 PC patients were prospectively enrolled from six hospitals, among which 431 patients were finally included.

Furthermore, C-statistic was employed to calibrate the discriminatory ability of the established clinical score, while a calibration plot was adopted for further assessment.

How the Study Was Run

Data from four of the six hospitals (n = 325) were used to develop the innovative clinical score (ICS), which was further validated using the data from the other two hospitals (n = 106).

To establish and validate the ICS, sequential logistic regression was used to analyse the clinical characteristics including tumour growth pattern and tumour size and so on.

What Was Measured

The subject headings attached to it are Body Height, Cohort Studies, Craniopharyngioma, Human Growth Hormone, Predictive Value of Tests and Tumor Burden.

Author keywords: Growth without growth hormone, Paediatric craniopharyngiomas and Tumour growth pattern.

What This Means in Plain Language

This is a clinical trial of Exogenous HGH, sermorelin & older GHRPs (why they're passed over) in 708 patients.

With several hundred people or more, it is a fairly large study for this kind of research.

The abstract goes on to report its results in about 5 sentences; this page does not restate them, so read the paper for the findings and their limits.

The publication is from 2020 (Journal of endocrinological investigation), a journal based in Italy.

More context: the Exogenous HGH, sermorelin & older GHRPs (why they're passed over) compound page, all human trials.

Our Notes on the Compound

Exogenous HGH, sermorelin & older GHRPs (why they're passed over): Constant levels suppress the body's own GHRH, raise somatostatin and dull pituitary response.

Exogenous HGH, sermorelin & older GHRPs (why they're passed over) in the library

Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.